Amgen Inc. $AMGN Shares Sold by Lineweaver Wealth Advisors LLC

Posted by George Bondi on Oct 13th, 2026

Lineweaver Wealth Advisors LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 36.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,221 shares of the medical research company’s stock after selling 2,938 shares during the period. Lineweaver Wealth Advisors LLC’s holdings in Amgen were worth $2,201,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. MW Advisory LLC bought a new position in shares of Amgen during the second quarter valued at approximately $1,054,000. Baird Financial Group Inc. raised its position in shares of Amgen by 1.6% during the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares during the period. Integrated Advisors Network LLC raised its position in shares of Amgen by 50.5% during the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after purchasing an additional 6,356 shares during the period. Nilsine Partners LLC acquired a new stake in shares of Amgen during the 2nd quarter worth approximately $3,329,000. Finally, KBC Group NV lifted its holdings in shares of Amgen by 51.7% in the 2nd quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after purchasing an additional 130,497 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN traded down $4.73 on Tuesday, reaching $412.84. The company had a trading volume of 2,319,557 shares, compared to its average volume of 2,748,310. Amgen Inc. has a one year low of $288.00 and a one year high of $447.03. The company has a market capitalization of $223.19 billion, a P/E ratio of 25.66, a PEG ratio of 2.99 and a beta of 0.41. The company has a fifty day moving average of $414.16 and a 200-day moving average of $373.24. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter last year, the business posted $6.02 earnings per share. The company’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. Oppenheimer restated an “outperform” rating on shares of Amgen in a research report on Wednesday, September 23rd. Barclays upped their price objective on Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. UBS Group increased their target price on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research report on Friday. Royal Bank Of Canada raised their target price on Amgen from $400.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Finally, HSBC downgraded shares of Amgen from a “buy” rating to a “hold” rating and reduced their price target for the company from $445.00 to $425.00 in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $387.93.

Check Out Our Latest Report on Amgen

Amgen Profile

(Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.